Connor, Clark & Lunn Investment Management (CC&L)’s Theravance Biopharma TBPH Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.05M	Sell	179,641 -70,114	-28%	-$1.16M	0.01%	877
2026 Q1	$4.05M	Buy	249,755 +28,093	+13%	+$497K	0.01%	747
2025 Q4	$4.15M	Buy	221,662 +46,825	+27%	+$777K	0.01%	703
2025 Q3	$2.55M	Buy	174,837 +118,224	+209%	+$1.49M	0.01%	782
2025 Q2	$624K	Buy	+56,613	New	+$550K	﹤0.01%	1191
2024 Q3	–	Sell	-16,023	Closed	-$136K	–	1635
2024 Q2	$136K	Buy	+16,023	New	+$145K	﹤0.01%	1291
2022 Q2	–	Sell	-40,477	Closed	-$387K	–	1194
2022 Q1	$387K	Buy	40,477 +7,443	+23%	+$72.9K	﹤0.01%	829
2021 Q4	$365K	Sell	33,034 -11,203	-25%	-$97.6K	﹤0.01%	863
2021 Q3	$327K	Buy	+44,237	New	+$495K	﹤0.01%	853

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TBPH Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Theravance Biopharma (TBPH) stake by 28% in Q2 2026, selling an estimated $1.16M and leaving 179,641 shares worth $3.05M. The position accounts for 0.01% of the portfolio, ranked #877.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TBPH in Q3 2021 and has held it in 9 quarters since. The position peaked at $4.15M in Q4 2025. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 179,641 shares of Theravance Biopharma worth $3.05M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 70,114 Theravance Biopharma shares in Q2 2026, an estimated $1.16M.
Theravance Biopharma made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #877 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Theravance Biopharma in Q3 2021 and has held it in 9 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Theravance Biopharma position peaked at $4.15M in Q4 2025.
179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.